Characteristic | Low-risk MGUSa N (%) | Other MGUSb N (%) | P valuec |
---|---|---|---|
Total | 12 (100) | 30 (100) | – |
Median years to myeloma diagnosis (range) | |||
First pre-diagnostic blood draw | 13.5 (6.8–18.7) | 11.1 (1.5–19.3) | 0.15 |
Second pre-diagnostic blood draw | 4.2 (0.2–11.6) | 3.0 (0.5–14.3) | 0.20 |
Median age at myeloma diagnosis in years (range) | 61 (48–84) | 62 (51–79) | 0.52 |
Sex | |||
Female | 7 (58) | 26 (87) | 0.09 |
Male | 5 (42) | 4 (13) | |
Isotype | |||
IgG | 12 (100) | 15 (50) | |
Non-IgG (IgA and IgD) | – | 7 (23) | |
Light-chain | – | 8 (27) | |
International staging system (ISS) stage | |||
ISS 1 | 5 (42) | 20 (67) | 0.17 |
ISS-2 or ISS-3 | 7 (58) | 10 (33) | |
Disease status at myeloma diagnosis | |||
Multiple myeloma (MM) | 10 (83) | 17 (57) | 0.16 |
Smoldering multiple myeloma (SMM) | 2 (17) | 13 (43) | |
Bone disease at myeloma diagnosisd | |||
Presence of MM bone disease | 8 (67) | 9 (30) | 0.04 |
Absence of MM bone disease | 4 (33) | 21 (70) | |
Imaging at myeloma diagnosis | |||
Only conventional skeletal survey | 7 (58) | 20 (67) | 0.73 |
Additional imaging modalitiese | 5 (42) | 10 (33) | |
Performance status | |||
ECOG 0–1 | 11 (92) | 26 (87) | 1.00 |
ECOG 2–3 | 1 (8) | 4 (13) | |
Diagnosis calendar period | |||
1997–2003 | 4 (33) | 9 (30) | |
2004–2007 | 3 (25) | 13 (43) | 0.49 |
2008–2012 | 5 (42) | 8 (27) | |
Median % clonal plasma cells (range) | 30 (10–80) | 21 (8–80)f | 0.20 |
Hemoglobing | |||
Normal | 3 (25) | 16 (53) | 0.17 |
Below normal | 9 (75) | 14 (47) | |
Creatinineh | |||
Normal | 7 (58) | 23 (77) | 0.27 |
Above normal | 5 (42) | 7 (23) | |
Corrected calcium | |||
Normal (2.15–2.50 mmol/L) | 11 (92) | 22 (73) | 0.25 |
Above normal (> 2.50 mmol/L) | 1 (8) | 8 (27) | |
Beta-2-microglobulin | |||
Normal (0.7–1.9 mg/L) | 2 (17) | 4 (13) | 1.00 |
Above normal (> 1.9 mg/L) | 10 (83) | 26 (87) | |
Lactate dehydrogenasei | |||
Normal | 9 (75) | 21 (70) | 1.00 |
Above normal | 3 (25) | 9 (30) |